PRODUCTS
Trading
Tools
PLATFORMS
PRICING
PROMOTION
LEARN
HUB
More from Webull
- About us
Our Partners
- Wall Street Journal
SUPPORT

LTRN

Lantern Pharma Inc

3.80

0.06+1.60%

After Hours: 3.890 +0.090 +2.37%16:43 03/14 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE3.750/3.740

TODAY RANGE3.570-3.850

VOL24.29K

MARKET CAP40.98M

52 WEEK RANGE2.790-11.99

AVG VOL (3M)94.08K

% TURNOVER0.23%

TURNOVER--

P/E (TTM)-2.1423

% RANGE7.48%

EPS(TTM)-1.7738

P/E(FORWARD)-1.9843

P/B1.541

BVPS2.466

DIVIDEND--

P/S1.195

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP34.95M

SHARES OUTSTANDING10.78M

NEXT EARNINGS03/17-03/21

FREE FLOAT9.20M

LOT SIZE1

EX-DIV DATE--

News

Press Releases

Financial Reports

Profile

Latest

Popular

TipRanks·01/27 16:10
Biotech Alert: Searches spiking for these stocks today
Benzinga·01/27 12:58
Lantern Pharma Advances Cancer Therapies With RADR Platform and Global ADC Collaborations
Reuters·01/27 12:57
LANTERN PHARMA : ANNOUNCES ADVANCEMENTS IN APPLICATION OF CO'S RADR AI PLATFORM TO ACCELERATE DEVELOPMENT OF ANTIBODY-DRUG CONJUGATES FOR CANCER
TipRanks·01/10 21:30
Lantern Pharma Extends CSO’s Employment Agreement
Benzinga·12/13/2024 21:06
12 Health Care Stocks Moving In Friday's Pre-Market Session
TipRanks·12/09/2024 14:30
Lantern Pharma doses first patient in LP-300 trial
Reuters·12/09/2024 13:15
LANTERN PHARMA ANNOUNCES FIRST PATIENT ENROLLED IN TAIWAN FOR PHASE 2 HARMONIC™ CLINICAL TRIAL OF LP-300 IN NEVER-SMOKER NSCLC PATIENTS
Dow Jones·12/03/2024 15:16
Lantern Pharma Shares Rise After Fast-Track Designation for Cancer Treatment
Reuters·12/03/2024 13:43
BUZZ-Lantern Pharma rises on FDA 'fast track' tag for breast cancer drug
TipRanks·12/03/2024 13:11
Lantern Pharma granted fast track designation for LP-184
Reuters·12/03/2024 13:00
LANTERN PHARMA'S INVESTIGATIONAL DRUG-CANDIDATE, LP-184, RECEIVES SECOND FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER (TNBC)
Reuters·11/26/2024 13:45
LANTERN PHARMA & STARLIGHT THERAPEUTICS PRESENT LP-184 (STAR-001) PHASE 1B TRIAL DESIGN AND PRECLINICAL DATA IN GLIOBLASTOMA AT SOCIETY FOR NEURO-ONCOLOGY (SNO) 2024 HIGHLIGHTING NOVEL SYNTHETIC LETHALITY
TipRanks·11/19/2024 13:21
Lantern Pharma doses first patient in LP-300 trial expansion cohort
Reuters·11/19/2024 13:00
LANTERN PHARMA ANNOUNCES FIRST PATIENT DOSED IN JAPAN FOR THE EXPANSION COHORT IN THE PHASE 2 HARMONIC™ CLINICAL TRIAL OF LP-300 IN NEVER-SMOKER NSCLC PATIENTS
TipRanks·11/08/2024 11:28
Lantern Pharma Discusses Q3 Financial Results Webinar

Same Industry

Name/Symbol

Change%

Price

Lantern Pharma Inc

LTRN

+1.60%

3.80

Regeneron Pharmaceuticals

REGN

-2.02%

666.87

Entero Therapeutics

ENTO

+2.12%

0.4820

BIONTECH

BNTX

+2.06%

99.47

United Therapeutics Corp.

UTHR

+0.61%

307.24

Siga Technologie

SIGA

+2.39%

5.58

Vertex Pharmaceuticals Inc

VRTX

+0.37%

504.77

Moderna

MRNA

+0.93%

34.62

Charles Riv Labs Intl Inc

CRL

+2.46%

171.04

Medpace Holdings

MEDP

+2.21%

324.95

Talphera Inc

TLPH

-0.89%

0.5600

ICON PLC

ICLR

+3.15%

184.58

China Biologic

CBPO

119.99

Iqvia Hldgs Inc

IQV

+2.07%

185.19

MOLECULAR PARTNERS AG

MOLN

-1.37%

4.33

Arcturus Therape

ARCT

+1.30%

14.08

Gilead Sciences Inc

GILD

-1.00%

111.44

PRA Health

PRAH

165.21

Aptevo Therapeutics Inc

APVO

+1.26%

2.41

Incyte Corp

INCY

+0.22%

67.86

Biospecifics

BSTC

+0.15%

88.53